Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma (NCT05199311) | Clinical Trial Compass
SuspendedPhase 1/2
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Stopped: Temporary Hold Pending Amendment Approval
United States66 participantsStarted 2022-05-13
Plain-language summary
This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Documented newly diagnosed multiple myeloma
. Patient should be deemed transplant eligible.
. Patients may not have had more than 1 cycle of prior induction therapy. If a patient has had 1 cycle of prior multiple myeloma therapy, the patient must have had documented measurable disease prior to initiation of cycle 1.
. Subjects must satisfy the following criteria to be enrolled in the study:
. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).
. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Rate of treatment emergent adverse events (TEAEs)
Timeframe: Measured after cycle 4 of induction KID (each cycle is 28 days)
2
CR and sCR
Timeframe: Measured after cycle 4 of induction KID (each cycle is 28 days)
. Subjects must have a documented diagnosis of MM and have measurable disease defined as:
Exclusion criteria
. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
. Subject has any condition that confounds the ability to interpret data from the study
. Subject has nonsecretory multiple myeloma
. Subjects with Plasma Cell leukemia or amyloidosis (with the exception of isolated marrow involvement).
. Any of the following laboratory abnormalities:
. Absolute neutrophil count (ANC) \< 1,000/μL
. Platelet count \< 50,000/μL. It is not permissible to transfuse subjects to achieve minimum platelet counts.